Lung cancer symptoms usually become apparent as the condition progresses as there tends to be no indications in the early stages. But when they do begin to show the most common sign is a cough. How can you tell if you have a normal cough or if it’s a lung cancer cough?
Oncimmune Plc (LON:ONC) is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 156,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK, Europe & Asia. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT®-Liver launched in May 2018 and further tests are in development.
